Co-Diagnostics (HAM:C970) FCF Margin %: -5,484.13% (As of Mar. 2026)

What is Co-Diagnostics FCF Margin %?

Co-Diagnostics HAM:C970 63 FCF Margin % is -5,484.13% as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Co-Diagnostics ranks worse than 97.06% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Co-Diagnostics's Free Cash Flow for the three months ended in Mar. 2026 was €-6.91 Mil. Co-Diagnostics's Revenue for the three months ended in Mar. 2026 was €0.13 Mil. Therefore, Co-Diagnostics's FCF Margin % for the quarter that ended in Mar. 2026 was -5,484.13%.

As of today, Co-Diagnostics's current FCF Yield % is -257.05%.

The historical rank and industry rank for Co-Diagnostics's FCF Margin % or its related term are showing as below:

HAM:C970' s FCF Margin % Range Over the Past 10 Years
Min: -41750 Med: -763.81 Max: 41.28
Current: -4049.68

During the past 11 years, the highest FCF Margin % of Co-Diagnostics was 41.28%. The lowest was -41750.00%. And the median was -763.81%.

HAM:C970's FCF Margin % is ranked worse than
97.06% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: -0.03 vs HAM:C970: -4049.68

Co-Diagnostics FCF Margin % Related Terms

Co-Diagnostics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics FCF Margin % Chart

Co-Diagnostics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

41.29

15.02

-344.18

-763.76

-4,798.68

Co-Diagnostics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-17,769.57	-5,343.26	-4,108.87	-2,403.11	-5,484.13

HAM:C970 vs CTSO, NMTC, RDGL: FCF Margin % Comparison

For the Medical Devices subindustry, Co-Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Co-Diagnostics FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's FCF Margin % falls into.

Save Embed

63GF Score

Co-Diagnostics Inc HAM:C970

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Co-Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Co-Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-25.481	/	0.531
	=	-4,798.68 %

Co-Diagnostics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-6.91	/	0.126
	=	-5,484.13 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -5,484.13% mean?

Co-Diagnostics (HAM:C970) has a FCF Margin % of -5,484.13% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Co-Diagnostics and its competitors. According to the industry distribution chart, Co-Diagnostics ranks #791 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 97.1%.

Is Co-Diagnostics' FCF Margin % too high?

Co-Diagnostics' current FCF Margin % is -5,484.13%. Based on the distribution chart, Co-Diagnostics ranks #791 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.

How does Co-Diagnostics' FCF Margin % compare to CTSO and NMTC?

According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #791 out of 815 companies for FCF Margin %. This places Co-Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Medical Devices & Instruments company?

A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current FCF Margin % is -5,484.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Co-Diagnostics stock overvalued right now?

Co-Diagnostics (HAM:C970) has a current FCF Margin % of -5,484.13%. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current FCF Margin % is -5,484.13%. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current FCF Margin % is -5,484.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.

Key valuation signals for HAM:C970:

FCF Margin %: -5,484.13%
GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CTSO NMTC RDGL PETV MODD FOFA VNRX GTHP LFWD NSYS ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges CODX:USA 0A50:UK

Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109

Website https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

63GF Score

Get the complete analysis for HAM:C970

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55

Price

€3.88

GF Value

View HAM:C970 Analysis

See FCF Margin % data for all stocks →